CUREVAC N V's ticker is CVAC and the CUSIP is N2451R105. A total of 89 filers reported holding CUREVAC N V in Q1 2024. The put-call ratio across all filers is 4.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $168,552 | +14.5% | 49,574 | +2.0% | 0.00% | – |
| Q1 2024 | $147,219 | -25.5% | 48,587 | +3.6% | 0.00% | – |
| Q4 2023 | $197,478 | -77.6% | 46,907 | -63.6% | 0.00% | – |
| Q3 2023 | $880,715 | -33.2% | 128,948 | +1.9% | 0.00% | – |
| Q2 2023 | $1,319,224 | -28.9% | 126,605 | -52.4% | 0.00% | – |
| Q1 2023 | $1,855,567 | -40.2% | 266,222 | -48.3% | 0.00% | – |
| Q4 2022 | $3,104,256 | +418.2% | 514,802 | +576.9% | 0.00% | – |
| Q3 2022 | $599,000 | -60.4% | 76,053 | -31.6% | 0.00% | – |
| Q2 2022 | $1,514,000 | -88.0% | 111,260 | -82.7% | 0.00% | -100.0% |
| Q1 2022 | $12,576,000 | -39.2% | 641,319 | +6.3% | 0.00% | 0.0% |
| Q4 2021 | $20,694,000 | -28.6% | 603,147 | +13.6% | 0.00% | -50.0% |
| Q3 2021 | $28,991,000 | -17.2% | 530,784 | +11.3% | 0.00% | 0.0% |
| Q2 2021 | $35,030,000 | +4300.8% | 476,727 | +5379.6% | 0.00% | – |
| Q1 2021 | $796,000 | – | 8,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 370,385 | $17,241,000 | 4.81% |
| Novo Holdings A/S | 201,642 | $9,386,000 | 0.47% |
| Vivo Capital, LLC | 169,825 | $7,905,000 | 0.46% |
| Baillie Gifford | 3,896,475 | $181,381,000 | 0.12% |
| DekaBank Deutsche Girozentrale | 435,500 | $21,707,000 | 0.10% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 69,176 | $3,220,000 | 0.08% |
| HHLR ADVISORS, LTD. | 186,183 | $8,667,000 | 0.07% |
| Pinz Capital Management, LP | 3,600 | $168,000 | 0.06% |
| Cutler Group LLC / CA | 18,400 | $856,000 | 0.05% |
| ETF MANAGERS GROUP, LLC | 35,722 | $1,632,000 | 0.05% |